Advertisement
Research Article| Volume 19, ISSUE 4, P797-814, December 1999

The Impact of Diagnostic Immunohistochemistry on Patient Outcomes

DOI:https://doi.org/10.1016/S0272-2712(18)30091-X
The Impact of Diagnostic Immunohistochemistry on Patient Outcomes
Previous ArticleCost-Based (Part A) Pathology Physician Services: Origin, Current Spectrum, and Future
Next ArticleThe Impact of Molecular Diagnostic Tests on Patient Outcomes
      This paper is only available as a PDF. To read, Please Download here.
      Diagnostic immunohistology (DIHC) is a discipline that has been used clinically for at least two decades, but, because of medicolegal encumbrances, it has not been a part of many formal outcomes analyses during that time. Potential applications of this technology with a direct bearing on response to treatment include the accurate identification of infectious organisms, distinction between morphologically-similar undifferentiated tumors, separation of benign and malignant neoplasms, and prognostication of malignancies. The first two of those four roles may indeed have a quantifiable impact on case outcomes, but the last two applications have only questionable value in this specific context. This is an area of medicine in which formal outcomes analysis is greatly needed to help determine future practice patterns.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Alberts A.S.
        • Falkson G.
        • Falkson H.C.
        • van der Merwe M.P.
        Treatment and prognosis of metastatic carcinoma of unknown primary: Analysis of 100 patients.
        Med Pediatr Oncol. 1989; 17: 188-192
        • Anagnostopoulos I.
        • Hummel M.
        • Kreschel C.
        • Stein H.
        Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: Implications for the interindividual infection route of Epstein-Barr virus.
        Blood. 1995; 85: 744-750
        • Anonymous
        Trastuzumab and capecitabine for metastatic breast cancer.
        Med Lett Drugs Ther. 1998; 40: 106-108
        • Ascani S.
        • Zinzani P.L.
        • Gherlinzoni F.
        • et al.
        Peripheral T-cell lymphomas: Clinicopatho-logic study of 168 cases diagnosed according to the REAL classification.
        Ann Oncol. 1997; 8: 583-592
        • Bergman R.
        • Dromi R.
        • Trau H.
        • et al.
        The pattern of HMB-45 antibody staining in compound Spitz nevi.
        Am J Dermatopathol. 1995; 17: 542-546
        • Blagosklonny M.V.
        Loss of function and p53 protein stabilization.
        Oncogene. 1997; 15: 1889-1893
        • Blumenschein G.R.
        • DiStefano A.
        • Caderao J.
        • et al.
        Multimodality therapy for locally advanced and limited stage IV breast cancer: The impact of effective non-crossresistance late-consolidation chemotherapy.
        Clin Cancer Res. 1997; 3: 2633-2637
        • Brawer M.K.
        • Peehl D.M.
        • Stamey T.A.
        • Bostwick D.G.
        Keratin immunoreactivity in the benign and neoplastic human prostate.
        Cancer Res. 1985; 45: 3663-3667
        • Brooks J.J.
        • LiVolsi V.A.
        • Pietra G.G.
        Mesothelial cell inclusions in mediastinal lymph nodes mimicking metastatic carcinoma.
        Am J Clin Pathol. 1990; 93: 741-748
        • Chan A.T.
        • Teo P.M.
        • Johnson P.J.
        Controversies in the management of locoregionally advanced nasopharyngeal carcinoma.
        Curr Opin Oncol. 1998; 10: 219-225
        • Cheng L.
        • Shan A.
        • Cheville J.C.
        • et al.
        Atypical adenomatous hyperplasia of the prostate: A premalignant lesion?.
        Cancer Res. 1998; 58: 389-391
        • Cheville J.C.
        • Reznicek M.J.
        • Bostwick D.G.
        The focus of “atypical glands, suspicious for malignancy” in prostatic needle biopsy specimens: Incidence, histologic features, and clinical followup of cases diagnosed in a community practice.
        Am J Clin Pathol. 1997; 108: 633-640
        • Cooper K.
        • Haffajee Z.
        • Taylor L.
        Comparative analysis of biotin intranuclear inclusions of gestational endometrium using the APAAP, ABC, and the PAP immunodetection systems.
        J Clin Pathol. 1997; 50: 153-156
        • Dehner L.P.
        The evolution of the diagnosis and understanding of primitive and embryonic neoplasms in children: Living through an epoch.
        Mod Pathol. 1998; 11: 669-685
        • Dehner L.P.
        On trial: A malignant small cell tumor in a child: four wrongs do not make a right.
        Am J Clin Pathol. 1998; 109: 662-668
        • DeMascarel I.
        • Bonichon F.
        • Coindre J.M.
        • Trojani M.
        Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Re-evaluation with longer followup.
        Br J Cancer. 1992; 66: 523-527
        • Drakos P.E.
        • Nagler A.
        • Or R.
        • et al.
        Invasive fungal sinusitis in patients undergoing bone marrow transplantation.
        Bone Marrow Transplant. 1993; 12: 203-208
        • Dranitsaris G.
        Treatment of non-Hodgkin’s lymphomas.
        Anticancer Drugs. 1998; 9: 879-888
        • Epstein J.I.
        The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens.
        Cancer. 1996; 78: 350-356
        • Fetsch P.A.
        • Marincola F.M.
        • Filie A.
        • et al.
        Melanoma-associated antigen recognized by T-cells (MART-1): The advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine needle aspiration.
        Cancer. 1999; 87: 37-42
        • Finkeistein S.D.
        • Tiffee J.C.
        • Bakker A.
        • et al.
        Malignant transformation in sinonasal papillomas is closely associated with aberrant p53 expression.
        Mol Diagn. 1998; 3: 37-41
        • Fizazi K.
        • Culine S.
        Metastatic carcinoma of unknown origin.
        Bull Cancer. 1998; 85: 609-617
        • Food and Drug Administration
        Medical Devices: Classification/Reclassification of Immunochemistry Reagents and Kits (21 CFR 864).
        Federal Register. 1998; 63: 30132-30142
        • Frew A.
        • Ralfkiaer N.
        • Ghosh A.K.
        • et al.
        Immunocytochemistry in the detection of bone marrow metastasis in patients with primary lung cancer.
        Br J Cancer. 1986; 53: 555-556
        • Freirson Jr, H.F.
        • Bellafiore F.J.
        • Gaffey M.J.
        • et al.
        Cytokeratin in anaplastic large cell lymphoma.
        Mod Pathol. 1994; 7: 317-321
        • Frost A.R.
        • Shek Y.H.
        • Lack E.E.
        “Signet ring” histiocytosis mimicking metastatic adenocarcinoma: Report of two cases with immunohistochemical and ultrastructural study.
        Mod Pathol. 1992; 5: 497-500
        • Funke I.
        • Schraut W.
        Meta-analysis of studies on bone marrow micrometastasis: An independent prognostic impact remains to be substantiated.
        J Clin Oncol. 1998; 16: 557-566
        • Gad A.
        • Willen H.
        • Willen R.
        • et al.
        Necrotizing sialometaplasia of the lip simulating squamous cell carcinoma.
        Histopathology. 1980; 4: 111-121
        • Gaffey M.J.
        The search for a “cancer stain” in diagnostic surgical pathology.
        Am J Clin Pathol. 1991; 96: 679-680
        • Gatter K.C.
        • Alcock C.
        • Heryet A.
        • Mason D.Y.
        Clinical importance of analysing malignant tumors of uncertain origin with immunohistological techniques.
        Lancet. 1985; 1: 1302-1305
        • Gatter K.C.
        • Mason D.Y.
        The use of monoclonal antibodies for histopathological diagnosis of human malignancy.
        Semin Oncol. 1982; 9: 517-525
        • Glickman J.N.
        • Torres C.
        • Wang H.H.
        • et al.
        The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma.
        Cancer. 1999; 85: 769-778
        • Googe P.B.
        • McGinley K.M.
        • Fitzgibbon J.F.
        Anticytokeratin antibody 34 beta E12 staining in prostate carcinoma.
        Am J Clin Pathol. 1997; 107: 219-223
        • Gottlieb T.M.
        • Oren M.
        p53 and apoptosis.
        Semin Cancer Biol. 1998; 8: 359-368
        • Gown A.M.
        • Vogel A.M.
        • Hoak D.
        • et al.
        Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes.
        Am J Pathol. 1986; 123: 195-203
        • Grotte D.
        • Stanley M.W.
        • Swanson P.E.
        • et al.
        Reactive type II pneumocytes in bronchoal-veolar lavage fluid from adult respiratory distress syndrome can be mistaken for cells of adenocarcinoma.
        Diagn Cytopathol. 1990; 6: 317-322
        • Hedrick L.
        • Epstein J.I.
        Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma.
        Am J Surg Pathol. 1989; 13: 389-396
        • Ingle R.R.
        • Setzen G.
        • Koltai P.J.
        • et al.
        p53 protein expression in benign lesions of the upper respiratory tract.
        Arch Otolaryngol Head Neck Surg. 1997; 123: 297-300
        • Johnston W.W.
        • Szpak C.A.
        • Lottich S.C.
        • et al.
        Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions.
        Cancer Res. 1985; 45: 1894-1900
        • Johnston W.W.
        • Szpak C.
        • Lottich S.C.
        • et al.
        Use of a monoclonal antibody (B72.3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens.
        Hum Pathol. 1986; 17: 501-513
        • Kuo T.T.
        • Chan J.K.C.
        Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
        Am J Surg Pathol. 1998; 22: 1474-1481
        • Lacueva F.J.
        • Teruel A.
        • Calpena R.
        • et al.
        Detection of p-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies.
        Histopathology. 1998; 32: 328-334
        • Lai R.
        • Arber D.A.
        • Chang K.L.
        • et al.
        Frequency of bcl-2 expression in non-Hodgkin’s lymphoma: A study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia.
        Mod Pathol. 1998; 11: 864-869
        • Leong A.S.Y.
        • Wick M.R.
        • Swanson P.E.
        Immunohistology and Electron Microscopy of Anaplastic and Pleomorphic Tumors. Cambridge University Press, Cambridge, UK1997: 209-240
        • Leong A.S.Y.
        • Wright J.
        The contribution of immunohistochemical staining in tumor diagnosis.
        Histopathology. 1987; 11: 1295-1305
        • Loy T.S.
        • Springer D.
        • Chapman R.K.
        • et al.
        Lack of specificity of monoclonal antibody B72.3 in distinguishing chronic pancreatitis from pancreatic adenocarcinoma.
        Am J Clin Pathol. 1991; 96: 684-688
        • Makris A.
        • Powles T.J.
        • Dowsett M.
        • et al.
        Prediction of response to neoadjuvant chemoenocrine therapy in primary breast carcinomas.
        Clin Cancer Res. 1997; 3: 593-600
        • Mangano W.E.
        • Cagle P.T.
        • Churg A.
        • et al.
        The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: A histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.
        Am J Clin Pathol. 1998; 110: 191-199
        • Masood S.
        • Hosein I.
        • Pitcher M.
        • Graf W.
        Potential value of immunoperoxidase technique in assessment of genital herpes.
        J Fla Med Assoc. 1990; 77: 516-519
        • Mathieu M.C.
        • Friedman S.
        • Bosq J.
        • et al.
        Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer.
        Breast Cancer Res Treat. 1990; 15: 21-26
        • Mayall F.
        • Heryet A.
        • Manga D.
        • Kreigeskotten A.
        p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology.
        Cytopathology. 1997; 8: 9-12
        • Morgan W.P.
        • Dundas S.A.C.
        • Howat A.J.
        Can monoclonal antibody B72.3 increase the sensitivity of fine needle aspiration cytology?.
        Br J Surg. 1988; 75: 1271
        • Ngan B.Y.
        • Picker L.J.
        • Medeiros L.J.
        • Warnke R.A.
        Immunophenotypic diagnosis of non-Hodgkin’s lymphoma in paraffin sections: Coexpression of L60 (Leu-22) and L26 antigens correlates with malignant histologic findings.
        Am J Clin Pathol. 1989; 91: 579-583
        • Niehans G.A.
        • Jaszcz W.
        • Brunetto V.
        • et al.
        Immunohistochemical identification of p-glycoprotein in previously untreated, diffuse large-cell and immunoblastic lymphomas.
        Cancer Res. 1992; 52: 3768-3775
        • Nuti M.
        • Teramoto Y.A.
        • Mariani-Costantini R.
        • et al.
        A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations.
        Int J Cancer. 1982; 29: 539-545
        • O’Sullivan M.J.
        • Ritter J.H.
        • Humphrey P.A.
        • Wick M.R.
        Lymphoid lesions of the gastrointestinal tract: A histologic, immunophenotypic, and genotypic analysis of 49 cases.
        Am J Clin Pathol. 1998; 110: 471-477
        • Pegram M.D.
        • Lipton A.
        • Hayes D.F.
        • et al.
        Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/ rcew-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
        J Clin Oncol. 1998; 16: 2659-2671
        • Perchalski J.E.
        • Hall K.L.
        • Dewar M.A.
        Metastasis of unknown origin.
        Prim Care. 1992; 19: 747-757
        • Picker L.J.
        • Weiss L.M.
        • Medeiros L.J.
        • et al.
        Immunophenotypic criteria for the diagnosis of non-Hodgkin’s lymphoma.
        Am J Pathol. 1987; 128: 181-201
        • Raab S.S.
        • Berg L.C.
        • Swanson P.E.
        • Wick M.R.
        Adenocarcinoma in the lung in patients with breast cancer: A prospective analysis of the discriminatory value of immunohistology.
        Am J Clin Pathol. 1993; 100: 27-35
        • Raab S.S.
        • Slagel D.D.
        • Hughes J.H.
        • et al.
        Sensitivity and cost-effectiveness of fine needle aspiration and immunocytochemistry in the evaluation of patients with a pulmonary malignancy and a history of cancer.
        Arch Pathol Lab Med. 1997; 121: 695-700
        • Ren S.
        • Lien E.J.
        Development of HIV protease inhibitors: A survey.
        Prog Drug Res. 1998; 51: 1-31
        • Ritter J.H.
        • Adesokan P.N.
        • Fitzgibbon J.F.
        • Wick M.R.
        Paraffin section immunohistochemistry as an adjunct to morphologic analysis in the diagnosis of cutaneous lymphoid infiltrates.
        J Cutan Pathol. 1994; 21: 481-493
        • Ritter J.H.
        • Sutton T.D.
        • Wick M.R.
        Use of immunostains to ABH blood group antigens to resolve problems in identity of tissue specimens.
        Arch Pathol Lab Med. 1994; 118: 293-297
        • Ritter J.H.
        • Wick M.R.
        • Reyes A.
        • et al.
        False-positive interpretations of carcinoma in exfoliative respiratory cytology: Report of two cases and a review of underlying disorders.
        Am J Clin Pathol. 1995; 104: 133-140
        • Ross J.S.
        • Fletcher J.A.
        The HER-2/new oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
        Stem Cells. 1998; 16: 413-428
        • Samra Z.
        • Kaufmann L.
        • Zeharia A.
        • et al.
        Optimal detection and identification of Mycobacterium haemophilum in specimens from pediatric patients with cervical lymphadenopathy.
        J Clin Microbiol. 1999; 37: 832-834
        • Schapira D.V.
        • Jarrett A.R.
        The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma.
        Arch Intern Med. 1995; 155: 2050-2054
        • Shibata D.
        Extraction of DNA from paraffin-embedded tissue for analysis by polymerase chain reaction: New tricks from an old friend.
        Hum Pathol. 1994; 25: 561-563
        • Shibata D.
        Identification of mismatched fixed specimens with a commercially available kit based on the polymerase chain reaction.
        Am J Clin Pathol. 1993; 100: 666-670
        • Swanson P.E.
        Labels, disclaimers, and rules (oh, my!): Analyte-specific reagents and practice of immunohistochemistry.
        Am J Clin Pathol. 1999; 111: 445-448
        • Swanson P.E.
        • Dehner L.P.
        • Sirgi K.E.
        • Wick M.R.
        Cytokeratin immunoreactivity in malignant tumors of bone and soft tissue.
        Appl Immunohistochem. 1994; 2: 103-112
        • Taylor C.R.
        FDA issues final rule for classification and reclassification of immunochemistry reagents and kits.
        Am J Clin Pathol. 1999; 111: 443-444
        • Tolbert D.M.
        • Noffsinger A.E.
        • Miller M.A.
        • et al.
        p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
        Mod Pathol. 1999; 12: 54-60
        • Travis W.D.
        • Pittaluga S.
        • Lipschik G.Y.
        • et al.
        Atypical pathological manifestations of Pneumocystis carinii pneumonia in the acquired immune deficiency syndrome: Review of 123 lung biopsies from 76 patients with emphasis on cysts, vascular invasion, vasculitis, and granulomas.
        Am J Surg Pathol. 1990; 14: 615-625
        • Warnke R.A.
        • Gatter K.C.
        • Falini B.
        • et al.
        Diagnosis of human lymphoma with monoclonal antileukocyte antibodies.
        N Engl J Med. 1983; 309: 1275-1281
        • White J.M.
        • Poupard J.A.
        • Knight R.A.
        • Miller L.A.
        Evaluation of two commercially available test methods to determine the feasibility of testing for respiratory syncytial virus in a community hospital laboratory.
        Am J Clin Pathol. 1988; 90: 175-180
        • Wick M.R.
        Oncogene analysis in diagnostic pathology: A current perspective.
        Am J Clin Pathol. 1992; 97: S1-S3
        • Wick M.R.
        • Loy T.
        • Mills S.E.
        • et al.
        Malignant epitheloid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: A histochemical, ultrastructural, and immunohistochemical study of 103 cases.
        Hum Pathol. 1990; 21: 759-766
        • Wick M.R.
        • Swanson P.E.
        • Rocamora A.
        Recognition of malignant melanoma by monoclonal antibody HMB-45.
        J Cutan Pathol. 1988; 15: 201-207
        • Wojno K.J.
        • Epstein J.I.
        The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer: A review of 228 cases.
        Am J Surg Pathol. 1995; 19: 251-260
        • Yang X.
        • Uziely B.
        • Groshen S.
        • et al.
        MDR1 gene expression in primary and advanced breast cancer.
        Lab Invest. 1999; 79: 271-280
        • Yang X.J.
        • Lecksell K.
        • Gaudin P.
        • Epstein J.I.
        Rare expression of high molecular weight cytokeratin in adenocarcinoma of the prostate gland: A study of 100 cases of metastatic and locally advanced prostate cancer.
        Am J Surg Pathol. 1999; 23: 147-152
        • Zerr D.M.
        • Frenkel L.M.
        Advances in antiviral therapy.
        Curr Opin Pediatr. 1999; 11: 21-27

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30091-X

      Copyright

      © 1999 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX